WuXi XDC Cayman, Inc. (HK:2268)
:2268
Want to see HK:2268 full AI Analyst Report?
Top Page
WuXi XDC Cayman, Inc.
(2268)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$63.00
▲(4.39% Upside)
Action:DowngradedDate:04/29/26
The score is driven primarily by strong financial performance—high margins, solid growth, and a conservative balance sheet—partly offset by uneven cash-flow conversion. Technicals are weak-to-neutral with the stock below key moving averages and slightly negative MACD. Valuation is a meaningful headwind given the high P/E and no dividend yield provided.
Positive Factors
Strong revenue growth
Consistent top-line expansion—revenue reached 5.79B in 2025 (+13.8% YoY) after multiple years of rapid expansion—signals sustained client demand and successful customer program progression. That trend supports higher GMP capacity utilization and strengthens pricing leverage over the medium term.
Negative Factors
Volatile cash conversion
Free cash flow has been inconsistent, with a large negative year in 2024 and only modest FCF in 2025 (~34% of net income). Uneven cash conversion can constrain discretionary capital allocation, slow capacity builds, and force dependence on external financing when customer billings or milestone timings shift.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Consistent top-line expansion—revenue reached 5.79B in 2025 (+13.8% YoY) after multiple years of rapid expansion—signals sustained client demand and successful customer program progression. That trend supports higher GMP capacity utilization and strengthens pricing leverage over the medium term.
Read all positive factors
WuXi XDC Cayman, Inc. (2268) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$73.10B
Dividend YieldN/A
Average Volume (3M)6.66M
Price to Earnings (P/E)46.0
Beta (1Y)1.11
Revenue Growth46.83%
EPS Growth36.46%
CountryHK
Employees2,041
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.70
Shares Outstanding1,260,343,300
10 Day Avg. Volume10,688,598
30 Day Avg. Volume6,656,062
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)6.18
Price to Sales (P/S)11.46
P/FCF Ratio104.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$82.20Price Target Upside36.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)1.64
Revenue Forecast (FY)HK$8.12B
WuXi XDC Cayman, Inc. Business Overview & Revenue Model
Company Description
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufac...
How the Company Makes Money
The company primarily makes money by charging pharmaceutical and biotechnology customers service fees under contract development and manufacturing arrangements for ADC programs. Key revenue streams generally include: (1) development services—fees ...
WuXi XDC Cayman, Inc. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.79B | 4.05B | 2.12B | 990.42M | 311.13M |
| Gross Profit | 2.08B | 1.24B | 559.56M | 261.08M | 113.49M |
| EBITDA | 1.73B | 1.33B | 420.28M | 151.75M | 77.37M |
| Net Income | 1.44B | 1.07B | 283.54M | 155.73M | 54.93M |
Balance Sheet | |||||
| Total Assets | 14.44B | 9.12B | 6.74B | 2.50B | 879.75M |
| Cash, Cash Equivalents and Short-Term Investments | 7.47B | 3.97B | 4.05B | 734.97M | 26.32M |
| Total Debt | 879.52M | 496.43M | 2.84M | 77.18M | 24.59M |
| Total Liabilities | 3.71B | 2.48B | 1.28B | 1.02B | 858.87M |
| Stockholders Equity | 10.73B | 6.64B | 5.45B | 1.48B | 20.88M |
Cash Flow | |||||
| Free Cash Flow | 634.64M | -787.95M | -206.51M | 50.43M | 7.23M |
| Operating Cash Flow | 1.85B | 717.22M | 332.85M | 251.82M | 59.14M |
| Investing Cash Flow | -1.43B | -3.33B | -91.23M | -1.28B | -51.59M |
| Financing Cash Flow | 2.80B | 475.36M | 3.52B | 1.33B | 22.34M |
WuXi XDC Cayman, Inc. Technical Analysis
Negative
60.35
Price Trends
60.15
Positive
63.75
Negative
63.11
Negative
Market Momentum
1.10
Negative
50.14
Neutral
53.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2268, the sentiment is Negative. The current price of 60.35 is above the 20-day moving average (MA) of 59.02, above the 50-day MA of 60.15, and below the 200-day MA of 63.11, indicating a neutral trend. The MACD of 1.10 indicates Negative momentum. The RSI at 50.14 is Neutral, neither overbought nor oversold. The STOCH value of 53.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2268.
WuXi XDC Cayman, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | HK$342.03B | 8.95 | 28.07% | 1.84% | 15.65% | 107.26% | |
75 Outperform | HK$29.50B | 15.86 | 3.65% | 0.15% | -17.60% | 316.24% | |
63 Neutral | HK$73.10B | 46.00 | 16.16% | ― | 46.83% | 36.46% | |
58 Neutral | HK$49.10B | -62.05 | 4.27% | 0.80% | 3.55% | 121.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2268
WuXi XDC Cayman, Inc.
59.25
21.35
56.33%
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
44.00
18.36
71.59%
HK:2359
WuXi AppTec Co., Ltd. Class H
143.10
84.00
142.13%
HK:6127
JOINN Laboratories (China) Co., Ltd. Class H
23.60
13.90
143.30%
WuXi XDC Cayman, Inc. Corporate Events
WuXi XDC Grants 4.85 Million Restricted Shares Under 2024 Incentive Scheme
Apr 8, 2026
WuXi XDC Cayman Inc. has approved the grant of 4,854,500 restricted shares at no purchase price to 425 grantees, including three directors and 422 employees, under its 2024 Share Scheme, with the shares to vest in four equal annual installments st...
WuXi XDC Cash Offers Close With Offeror Gaining Majority Control
Mar 31, 2026
WuXi XDC Cayman Inc. and BioDlink International Company Limited announced the close of voluntary conditional cash offers for WuXi XDC shares and share options, which were made on behalf of the offeror by Citigroup Global Markets Asia. The offeror ...
WuXi XDC Posts Strong 2025 Profit Growth but Withholds Final Dividend
Mar 23, 2026
WuXi XDC Cayman Inc., a Hong Kong-listed biopharmaceutical services provider incorporated in the Cayman Islands, specializes in contract development and manufacturing for innovative therapeutics, serving global pharma and biotech customers. Its bu...
WuXi XDC to Present 2025 Results in Dual Conference Calls on March 24, 2026
Mar 23, 2026
WuXi XDC Cayman Inc. has announced that it will hold two conference calls on March 24, 2026, to present its 2025 annual results and discuss business operations with shareholders and potential investors. The company has also released the full prese...
WuXi XDC Cash Offer Turns Unconditional as Offeror Secures Majority Control
Mar 17, 2026
WuXi XDC Cayman Inc. and BioDlink International announced that voluntary conditional cash offers for all issued shares of WuXi XDC, excluding those already held by the offeror and its concert parties, and for the cancellation of all outstanding sh...
WuXi XDC tender offer reaches 46.5% acceptances, short of control threshold
Mar 13, 2026
WuXi XDC Cayman Inc. and BioDlink International Company Limited disclosed that a voluntary conditional cash offer for WuXi XDC’s shares and share options has drawn substantial, but not yet controlling, support from stakeholders. As of the fi...
WuXi XDC Sends Composite Document for Voluntary Cash Offers and Option Cancellation
Feb 11, 2026
WuXi XDC Cayman Inc. and BioDlink International Company Limited jointly announced the dispatch of a composite offer and response document for voluntary conditional cash offers for all issued shares of WuXi XDC not already owned by the offeror and ...
WuXi XDC Delays Dispatch of Composite Document for Voluntary Cash Offers
Feb 4, 2026
WuXi XDC Cayman Inc., together with offeror BioDlink International Company Limited and associate WuXi Biologics, has announced a delay in sending a composite offer document related to voluntary conditional cash offers for all issued shares not alr...
WuXi XDC Delays Shareholder Circular on Offer Transactions After HKEX Waiver
Feb 4, 2026
WuXi XDC Cayman Inc. has announced a delay in sending a shareholder circular related to previously announced offers to acquire offer shares and cancel share options, transactions that have already been approved by written consent from controlling ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.